2-Methoxyestradiol
| Clinical data | |
|---|---|
| Trade names | Panzem | 
| Other names | 2-ME2; 2-MeO-E2; 2-MeOE2; 2-Hydroxyestradiol 2-methyl ether; 2-Methoxyestra-1,3,5(10)-triene-3,17β-diol | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.606 | 
| Chemical and physical data | |
| Formula | C19H26O3 | 
| Molar mass | 302.414 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
2-Methoxyestradiol (2-ME2, 2-MeO-E2) is a natural metabolite of estradiol and 2-hydroxyestradiol (2-OHE2). It is specifically the 2-methyl ether of 2-hydroxyestradiol. 2-Methoxyestradiol prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis), hence it is an angiogenesis inhibitor. It also acts as a vasodilator and induces apoptosis in some cancer cell lines. 2-Methoxyestradiol is derived from estradiol, although it interacts poorly with the estrogen receptors (2,000-fold lower activational potency relative to estradiol). However, it retains activity as a high-affinity agonist of the G protein-coupled estrogen receptor (GPER) (10 nM, relative to 3–6 nM for estradiol).
| Estrogen | ER RBA (%) | Uterine weight (%) | Uterotrophy | LH levels (%) | SHBG RBA (%) | 
|---|---|---|---|---|---|
| Control | – | 100 | – | 100 | – | 
| Estradiol (E2) | 100 | 506 ± 20 | +++ | 12–19 | 100 | 
| Estrone (E1) | 11 ± 8 | 490 ± 22 | +++ | ? | 20 | 
| Estriol (E3) | 10 ± 4 | 468 ± 30 | +++ | 8–18 | 3 | 
| Estetrol (E4) | 0.5 ± 0.2 | ? | Inactive | ? | 1 | 
| 17α-Estradiol | 4.2 ± 0.8 | ? | ? | ? | ? | 
| 2-Hydroxyestradiol | 24 ± 7 | 285 ± 8 | +b | 31–61 | 28 | 
| 2-Methoxyestradiol | 0.05 ± 0.04 | 101 | Inactive | ? | 130 | 
| 4-Hydroxyestradiol | 45 ± 12 | ? | ? | ? | ? | 
| 4-Methoxyestradiol | 1.3 ± 0.2 | 260 | ++ | ? | 9 | 
| 4-Fluoroestradiola | 180 ± 43 | ? | +++ | ? | ? | 
| 2-Hydroxyestrone | 1.9 ± 0.8 | 130 ± 9 | Inactive | 110–142 | 8 | 
| 2-Methoxyestrone | 0.01 ± 0.00 | 103 ± 7 | Inactive | 95–100 | 120 | 
| 4-Hydroxyestrone | 11 ± 4 | 351 | ++ | 21–50 | 35 | 
| 4-Methoxyestrone | 0.13 ± 0.04 | 338 | ++ | 65–92 | 12 | 
| 16α-Hydroxyestrone | 2.8 ± 1.0 | 552 ± 42 | +++ | 7–24 | <0.5 | 
| 2-Hydroxyestriol | 0.9 ± 0.3 | 302 | +b | ? | ? | 
| 2-Methoxyestriol | 0.01 ± 0.00 | ? | Inactive | ? | 4 | 
| Notes: Values are mean ± SD or range. ER RBA = Relative binding affinity to estrogen receptors of rat uterine cytosol. Uterine weight = Percentage change in uterine wet weight of ovariectomized rats after 72 hours with continuous administration of 1 μg/hour via subcutaneously implanted osmotic pumps. LH levels = Luteinizing hormone levels relative to baseline of ovariectomized rats after 24 to 72 hours of continuous administration via subcutaneous implant. Footnotes: a = Synthetic (i.e., not endogenous). b = Atypical uterotrophic effect which plateaus within 48 hours (estradiol's uterotrophy continues linearly up to 72 hours). Sources: See template. | |||||